Last reviewed · How we verify
ezogabine/retigabine
Ezogabine opens voltage-gated potassium channels in neurons, increasing potassium efflux and reducing neuronal excitability to suppress seizures.
Ezogabine opens voltage-gated potassium channels in neurons, increasing potassium efflux and reducing neuronal excitability to suppress seizures. Used for Partial-onset seizures (adjunctive therapy).
At a glance
| Generic name | ezogabine/retigabine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Potassium channel opener; anticonvulsant |
| Target | KCNQ potassium channels (Kv7) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Ezogabine is a potassium channel opener that stabilizes the open state of KCNQ (Kv7) voltage-gated potassium channels. By enhancing potassium channel activity, it hyperpolarizes neuronal membranes and reduces the likelihood of action potential firing, thereby decreasing seizure activity. This mechanism is distinct from other anticonvulsants and provides an alternative approach to seizure control.
Approved indications
- Partial-onset seizures (adjunctive therapy)
Common side effects
- Dizziness
- Somnolence
- Confusion
- Vertigo
- Tremor
- Diplopia
- Urinary retention
- Blue discoloration of skin/sclera
Key clinical trials
- Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer: A Multicenter Propensity Score Matching Analysis
- An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE (PHASE3)
- XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (PHASE3)
- Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures (PHASE4)
- An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures (PHASE4)
- Study in Pediatric Subjects With Epilepsy (PHASE2)
- Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS (PHASE3)
- Study to Treat Major Depressive Disorder With a New Medication (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ezogabine/retigabine CI brief — competitive landscape report
- ezogabine/retigabine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI